MBX Biosciences Adds New Director Following Shareholder Vote

MBX Biosciences Inc. reported the election of one new director and the departure of another at its annual shareholder meeting held on June 4, 2026.

The company disclosed both actions in an 8-K filed with the SEC on June 5, 2026. Item 5.07 of the filing covers the submission of matters to a vote of security holders, while Item 5.02 addresses the departure and election of directors.

The board now consists of its prior members minus the departing director plus the newly elected director. The filing does not name the individuals, cite a cause for the resignation, or specify an effective date beyond the meeting itself. No changes to executive officers such as the chief executive or chief financial officer were reported.

Operationally the company must update its board roster in future SEC filings, including any revisions to committee memberships or independence determinations required under Nasdaq listing rules. The new director will participate in all subsequent board decisions and the company will file a separate Form 4 if the election involved any compensatory equity grants.

Downstream, the change requires MBX to disclose the new director’s biographical information, related-party transactions and committee assignments in its next proxy statement or 10-K. If the departing director held a committee seat, the board must appoint a replacement to maintain compliance with audit, compensation or nominating committee charters.

Standard Form 8-K Item 5.02 disclosure deadlines have already been met with this filing.

This marks the latest board-level change for the clinical-stage biotechnology company, which went public in 2021. The 8-K follows routine annual-meeting disclosures required of all Nasdaq-listed companies under SEC rules.